Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05546476 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT05546476 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 187 participants.
The verdict
NCT05546476, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
Interventions
- DRUG ponsegromab
- DRUG Placebo for ponsegromab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05546476
The ClinicalTrials.gov registry entry for NCT05546476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ponsegromab is the first listed.
NCT05546476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05546476 about?
NCT05546476 is a clinical study titled "Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15". Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
What is the current status of trial NCT05546476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2022-11-21. Estimated completion is 2025-04-23.
What interventions are being tested in trial NCT05546476?
The interventions under investigation include: ponsegromab (DRUG), Placebo for ponsegromab (DRUG).
Who is sponsoring clinical trial NCT05546476?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.